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Background: The 2011 idiopathic pulmonary fibrosis (IPF) guidelines are based on the diagnosis of IPF using only
high-resolution computed tomography (HRCT). However, few studies have thus far reviewed the usefulness of the
HRCT scoring system based on the grading scale provided in the guidelines. We retrospectively studied 98 patients
with respect to assess the prognostic value of changes in HRCT findings using a new HRCT scoring system based
on the grading scale published in the guidelines.
Methods: Consecutive patients with IPF who were diagnosed using HRCT alone between January 2008 and
January 2012 were evaluated. HRCT examinations and pulmonary function tests were performed at six-month
intervals for the first year after diagnosis. The HRCT findings were evaluated using the new HRCT scoring system
(HRCT fibrosis score) over time. The findings and survival rates were analyzed using a Kaplan-Meier analysis.
Results: The HRCT fibrosis scores at six and 12 months after diagnosis were significantly increased compared to
those observed at the initial diagnosis (p < 0.001). The patients with an elevated HRCT fibrosis score at six months
based on a receiver operating characteristic (ROC) curves analysis had a poor prognosis (log-rank, hazard ratio [HR]
2.435, 95% CI 1.196-4.962; p = 0.0142). Furthermore, among the patients without marked changes in %FVC, those
with an elevated score above the cut-off value had a poor prognosis (HR 2.192, 95% CI 1.003-4.791; p = 0.0491).
Conclusions: Our data demonstrate that the HRCT scoring system based on the grading scale is useful for
predicting the clinical outcomes of IPF and identifying patients with an adverse prognosis when used in
combination with spirometry.
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Idiopathic pulmonary fibrosis (IPF) is a progressive and
generally fatal disease. Several retrospective studies have
suggested that the condition is associated with a median
survival time of only two to three years after diagnosis
[1-5].
The 2011 IPF guidelines provide updated and simplified
IPF diagnostic criteria proposed by the ATS/ERS/JRS/
ALAT [6]. This may result in HRCT scanning playing a* Correspondence: hmukae@med.uoeh-u.ac.jp
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unless otherwise stated.central role in the diagnosis of IPF. According to the
guidelines that include major changes in the process of
the diagnosis of IPF, the exclusion of other known causes
of interstitial lung disease in addition to the detection of
the usual interstitial pneumonia (UIP) pattern on high-
resolution computed tomography (HRCT) in patients not
subjected to surgical lung biopsies (SLBs) is adequate to
diagnose the disease.
Furthermore, the 2011 IPF guidelines state that disease
progression manifests as worsening respiratory symp-
toms, worsening pulmonary functions, the presence of
progressive fibrosis on HRCT and acute respiratory. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cessary to detect the development of the disease and
proactively identify those with progressive disease. Add-
itionally, pulmonary function tests are considered to be
the most standardized approach for objectively monitor-
ing and quantifying disease progression. In clinical prac-
tice, it is sometimes difficult to evaluate the progression
of the disease based only on a worsening of the pulmon-
ary function due to patient’s non-cooperation.
On the other hand, technological advances in HRCT
have brought about decreases in examination times and
the ability to obtain clearer images of secondary pulmon-
ary lobules without the need for patient cooperation,
unlike spirometry. Therefore, HRCT is an accurate, sen-
sitive and objective technique for evaluating IPF. In
addition, physicians often experience patients who ex-
hibit worsening of HRCT findings associated with a poor
prognosis in clinical practice. However, the use of regular
follow-up with chest HRCT remains controversial in rou-
tine clinical practice and the procedure is not currently
recommended in clinically stable patients.
The aim of our study was to assess the prognostic value
of changes in HRCT findings using a new HRCT scoring




Our institutional review board approved this retrospect-
ive study (approval number H24-174, February 20,
2013), with a waiver of informed consent due to the
retrospective study design. All consecutive patients diag-
nosed with IPF between January 2008 and January 2012
were enrolled in this study. All patients with IPF diag-
nosed using HRCT alone according to the 2011 IPF
guidelines (the presence of an UIP pattern, including all
four of the following features: subpleural features, basal
predominance, reticular abnormalities, honeycombing
with or without traction bronchiectasis) and the absence
of features inconsistent with the UIP pattern were in-
cluded. The patients were also diagnosed based on the
exclusion of a possible UIP pattern associated with other
known causes of interstitial lung disease, such as chronic
hypersensitivity pneumonia, occupational or environ-
mental exposure, connective tissue disease and drug-
induced pneumonia. HRCT examinations, pulmonary
function tests and serological studies were performed
every six months from the initial diagnosis (baseline).
Patients with missing or failed inspiratory chest CT
scans were excluded from this study. An acute exacerba-
tion was defined as the acute onset of increased dyspnea
and hypoxia with progressive infiltrates on HRCT within
the preceding 30 days in the absence of infection, pul-
monary embolism or cardiac failure [7].HRCT assessment and HRCT fibrosis score
HRCT scans were obtained with 1-mm collimation and
a 1-mm slice thickness at 10-mm intervals from the lung
apices to the bases with the patient in the supine pos-
ition at full inspiration. Two observers [H.I, K.N.] who
were unaware of the clinical data and lung function of
the patients (all the HRCT images were assessed in ran-
dom order) evaluated the data independently. The ob-
servers made a subjective assessment of the overall
extent of normal attenuation, reticular abnormalities,
honeycombing and traction bronchiectasis.
A reticular abnormality was defined as a collection of
innumerable areas of small linear opacity [1]. Honey-
combing was defined as the presence of a cystic airspace
measuring 3–10 mm in diameter, with 1- to 3-mm thick
walls [8]. Traction bronchiectasis was defined as irregu-
lar bronchial dilatation within the surrounding areas
showing parenchymal abnormalities. The morphological
criteria on HRCT scans included bronchial dilatation
with respect to the accompanying pulmonary artery, a
lack of tapering of the bronchi and the identification of
bronchi within 10 mm of the pleural surface [8].
The HRCT findings were graded on a scale of 1–4
based on the classification system: 1. normal attenuation;
2. reticular abnormality; 3. traction bronchiectasis; and
4. honeycombing. The assessments of the two observers
were averaged. This grading scale and assessed zones
were determined based on the previous reports by Ichi-
kado et al. [9,10] with minor changes for this study. The
presence of each of the above four HRCT findings was
assessed independently in three (upper, middle and
lower) zones of each lung. The upper lung zone was de-
fined as the area of the lung above the level of the tra-
cheal carina, the lower lung zone was defined as the area
of the lung below the level of the inferior pulmonary
vein and the middle lung zone was defined as the area of
the lung between the upper and lower zones. The extent
of each HRCT finding was determined by visually esti-
mating the percentage (to the nearest 5%) of parenchy-
mal involvement in each zone. The score for each zone
was calculated by multiplying the percentage of the area
by the grading scale score [1-4]. The six zone scores
were averaged to determine the total score for each pa-
tient. The highest score was 400 points and the lowest
score was 100 points using this calculation method. We
named the total score the “HRCT fibrosis score”. The
HRCT fibrosis score was recorded at the initial diagnosis
and after six and 12 months in a similar manner, and an
investigation was conducted regarding the chronological
changes in these values.
Physiological testing
Pulmonary function tests, including spirometry and an
assessment of the diffusing capacity of the lungs for
Table 2 The distributions of and interobserver agreement
between the two observers at baseline
HRCT findings κ value* (p-value) ICC† (95% CI)
Normal attenuation 1.00 (< 0.001) 0.91 (0.83-0.95)
Reticular abnormality 0.65 (0.023) 0.83 (0.72-0.91)
Traction bronchiectasis 0.78 (0.031) 0.81 (0.66-0.89)
Honeycombing 0.82 (0.007) 0.77 (0.62-0.87)
*The interobserver agreement regarding the presence/absence of HRCT
findings between the two observers was assessed by the kappa statistics
(κ value).
†The interobserver agreement regarding the extent of the HRCT findings
between the two observers was analyzed for the square root of the normal
attenuation, reticular abnormality, traction bronchiectasis and honeycombing
by Fleiss’s ICC.
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dardized spirometry procedure [11] on the same day as
the HRCT examination. The degree of improvement
was defined based on 10% absolute changes in the
forced vital capacity (FVC) from the baseline values as
“improved (≥ 10% increase),” “stable (< 10% change)” or
“worsened (≥ 10% decrease)” using the FVC values mea-
sured at six and 12 months after the initial diagnosis. In
the present study, disease progression was defined as the
presence of acute exacerbation, a ≥10% absolute de-
crease in the FVC and/or a ≥15% decrease in the %DLCO
from the baseline value, as determined according to pul-
monary function tests [12].
Statistical analysis
The mean ± standard deviation (SD) values of the pulmon-
ary function parameters, HRCT fibrosis score and other
continuous variables were determined at baseline and at
six and 12 months. The paired t-test was performed to
evaluate the changes in the variables from the baseline to
six and 12 months, respectively. The interobserver vari-
ation with respect to the presence/absence of HRCT find-
ings at baseline was evaluated using the kappa statistic
based on the diagnosis made prior to the assessment by
consensus [13]. The interobserver agreement was catego-
rized as “poor (κ < 0.20),” “fair (0.21 < κ < 0.40),” “moderate
(0.41 < κ < 0.60),” “substantial (0.61 < κ < 0.80)” or “almost
perfect (0.81 < κ < 1.00).” The interobserver variationTable 1 Baseline characteristics and physiology of
patients
Patient, No 98
Sex, male/female, No 55/43
Age, year, mean ± SD 70.6 ± 8.0
BMI, kg/m2, mean ± SD 23.1 ± 3.4
Smoker (current/former/never) 17/52/29
PaO2, Torr, mean ± SD 80.9 ± 15.1
SpO2,%, mean ± SD 96.0 ± 2.51
FVC, L, mean ± SD 2.14 ± 0.80
%FVC,%, mean ± SD 71.0 ± 20.8
FEV1.0%,%, mean ± SD 85.1 ± 9.15
DLCO, ml/min/mmHg, mean ± SD 9.51 ± 2.83
%DLCO,%, mean ± SD 60.0 ± 19.7
KL-6, U/ml, mean ± SD 1319 ± 996
SP-D, ng/ml, mean ± SD 302.2 ± 213.2
LDH, IU/L, mean ± SD 236.2 ± 43.7
MMRC score (0/1/2/3/4) 15/38/24/21/0
HRCT score, mean ± SD 134.2 ± 27.5
Receiving immunosuppressive therapy, No 27
BMI = body mass index, FVC = forced vital capacity, DLCO = diffusing capacity
for carbon monoxide, KL-6 = Krebs von den Lungen-6, SP-D = surfactant
protein-D, MMRC =modified medical research council.regarding the extent of the HRCT findings at baseline and
the changes in the extent of honeycombing from baseline
to follow-up at six and 12 months were evaluated using
Fleiss’s intraclass correlation coefficient (ICC) [14].
Univariate Cox’s proportional hazard models were
used to determine the ability of each variable to predict
mortality. Additionally, the stepwise multivariate Cox’s
proportional hazards model was used for variables found
to be significant (p < 0.05) in the univariate model in
order to identify more significant variables.
To analyze the changes in the HRCT fibrosis score
(ΔHRCT fibrosis score) from baseline to follow-up (after
six or 12 months) as a predictor of disease progression
(as stated previously) within one year, we used receiver
operating characteristic (ROC) curves and the corre-
sponding area under the curve. The cut-off value for the
test was selected based on an analysis of the tabular
ROC curve data in order to obtain the best possible sen-
sitivity and specificity. Furthermore, the cut-off value
was used to investigate whether the presence of an in-
crease, as determined using the cut-off value, after six
months or 12 months was related to the overall survival.
The rates of overall survival were estimated using the
Kaplan-Meier method and compared using the log-rank
test. The patients were divided into groups based on %
FVC at six months and the degree of disease progression
according to the HRCT fibrosis score, and the overall
survival was studied. All statistical analyses were per-
formed using the Statistical Package for Social SciencesTable 3 Distributions of and interobserver agreement for
the changes in the extent of honeycombing from
baseline
From baseline ICC (95% CI)
at 6 months 0.91 (0.83-0.95)
at 12 months 0.83 (0.68-0.91)
The interobserver agreement regarding the changes in the extent of
honeycombing between the two observers were analyzed for the square root
of the values at six and 12 months by Fleiss’s ICC.
Table 4 Results the univariate and multivariate Cox
proportional hazard models of independent predictors of
mortality
Univariate Cox proportional hazard model
Variable p-value HR (95% Cl)
Age 0.219 1.023 (0.985 to 1.062)
BMI 0.292 0.937 (0.829 to 1.058)
PaO2 0.193 0.982 (0.955 to 1.009)
%FVC 0.002 0.968 (0.948 to 0.989)
KL-6 0.028 1.000 (1.000 to 1.001)
MMRC score 0.013 1.659 (1.111 to 2.478)
HRCT score 0.268 1.007 (0.995 to 1.019)
Multivariate Cox proportional hazard model
%FVC 0.037 0.972 (0.958 to 0.986)
KL-6 0.100 1.000 (1.000 to 1.001)
MMRC score 0.043 1.240 (1.005 to 2.475)
BMI = body mass index, FVC = forced vital capacity, KL-6 = Krebs von den
Lungen-6, MMRC =modified medical research council.
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cance level of p < 0.05.
Results
Patient characteristics
The baseline demographic, clinical and biological char-
acteristics of the participants are summarized in Table 1.
All patients were confirmed to be dead/alive as of April
1, 2013. The mean ± SD observation period was 30 ±
18.8 months, and 35 patients (35.7%) died during the
observation period, including 17 (17.3%) due to acute
exacerbation, 10 (10.2%) due to respiratory failure, four
(4.1%) due to cancer and four (4.1%) due to other known
causes. The median survival time of all participants was
45.8 months.
Interobserver agreement and correlation
The interobserver agreement with regard to the presence
of HRCT findings ranged from substantial to almost per-
fect (κ value, 0.65-1.00), as did the interobserver agree-
ment regarding the extent of HRCT findings between
the two observers ranged [15] (ICC, 0.77-0.91) (Table 2).7.2
7.2
73.5




Figure 1 The results of the categorical analysis based on the changes
Improvement ratings were defined based on a 10% absolute change as “im
“worsened” for a ≥ 10% decrease.The interobserver agreement regarding the changes in
the extent of honeycombing between the two observers
was also almost perfect (ICC, 0.91 and 0.83) (Table 3).
Prognostic factors for mortality
The results of the univariate Cox proportional hazard
model are shown in Table 4. The %FVC (hazard ratio
(HR) 0.968, 95% CI 0.948-0.989; p = 0.002), KL-6 (HR
1.000, 95% CI 1.000-1.001; p = 0.028) and modified Med-
ical Research Council (MMRC) score (HR 1.659, 95% CI
1.111-2.478; p = 0.013) were identified to be significantly
predictive of survival. In this analysis, the HRCT fibrosis
score at baseline was not found to be significantly re-
lated to the prognosis. Meanwhile, the multivariate Cox
proportional analysis demonstrated the %FVC (HR
0.972, 95% CI 0.958-0.986; p = 0.037) and MMRC score
(HR 1.240, 95% CI 1.005-2.475; p = 0.043) to be signifi-
cant factors predicting the prognosis of patients with
IPF.
Time-dependent changes in %FVC and the stratified
survival analysis
The %FVC values “improved” at six and 12 months after
the initial diagnosis in seven and seven patients (7.2%
and 7.2%), remained “stable” in 85 and 73 patients
(86.7% and 73.5%) and “worsened” in six and 18 patients
(6.1% and 19.1%), respectively, thus indicating worsening
of %FVC over time (Figure 1).
The positive and negative predictive values with the rat-
ings at six months for the prediction of those at 12
months are shown in Table 5. In this analysis, the “wors-
ened” at six months was still present at 12 months at a
relatively high rate (positive predictive value: 66.7% (4/6)),
and the “non-worsened” status group at six months
remained relatively stable at 12 months with a high rate
(negative predictive value: 83.7% (77/92)). Additionally,
the overall survival analysis of the patients divided into
two groups according to the presence or absence of a
“worsened” status at six months showed that the “wors-
ened” status group had a poorer prognosis (log-rank test,
HR 4.424, 95% CI 1.087-18.02; p = 0.0397) (Figure 2).
The median survival rates of the “non-worsened” and86.7
19.1
6.1
50% 60% 70% 80% 90% 100%
table" "worsened"
in the FVC from baseline. The %FVC declined with time.
proved” for a ≥ 10% increase, “stable” for a < 10% change and
Table 5 Positive and negative predictive values at six
months for predicting the ratings at 12 months
at 12 months
worsened* Non-worsened†
at 6 months worsened 4 (66.7%) 2 (33.3%) 6
Non-worsened 15 (16.3%) 77 (83.7%) 92
19 79 98
*Worsened was defined based on 10% absolute decreasing changes in the
FVC from baseline.
†Non-worsened indicated improved (≥ 10% increase) and stable
(< 10% change) status.
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respectively.
Time-dependent changes in the HRCT fibrosis score and
the stratified survival analysis
The overall extent of pulmonary parenchymal abnormal-
ities on the initial diagnosis and at six and 12 months is
summarized in Figure 3. In line with the changes ob-
served at six and 12 months after the initial diagnosis,
the extent of normal attenuation was reduced, while that
of reticular abnormalities, honeycombing and traction
bronchiectasis was increased. Furthermore, the average
HRCT fibrosis score increased over time, with scores of
134.2, 139.6 and 147.8 at baseline and six and 12
months, respectively (p < 0.001) (Figures 4 and 5).
The area under the ROC curve for the ΔHRCT fibrosis
score was used to significantly classify patients with re-










(HR: 4.424 ; 95% CI: 1.087 to 18.
Figure 2 The results of the Kaplan-Meier analysis of the overall surviv
was significantly worse than that of the “non-worsened” status group at six95% CI 0.518-0.871; p = 0.033, 0.712; 95% CI 0.542-
0.881; p = 0.024, respectively). The optimal cut-off value
for the ΔHRCT fibrosis score was 6.7 and 13.5 at six and
12 months, respectively, based on the Youden index,
with a sensitivity and specificity of the respective diag-
nostic performance for predicting disease progression of
0.64 (95% CI 0.31-0.89) and 0.72 (95% CI 0.60-0.81) at
six months and 0.82 (95% CI 0.48-0.98) and 0.64 (95%
CI 0.52-0.75) at 12 months, respectively.
Patients with an elevated ΔHRCT fibrosis score above
the cut-off value at six (HR 2.435, 95% CI 1.196-4.962; p =
0.0142) (Figure 6A) and 12 months (HR 2.637, 95% CI
1.363-5.100; p = 0.004) (Figure 6B) compared to that ob-
served at baseline had a significantly worse prognosis than
those with lower scores.Survival analysis using a combination of the HRCT fibrosis
score and %FVC
At six months, the patients with increased HRCT fibrosis
scores above the cut-off value in addition to a “worsened”
status regarding the %FVC had a clearly poorer prognosis
(HR 28.47, 95% CI 2.649-306.5; p = 0.0057). Furthermore,
in the comparison of the overall survival based on whether
the HRCT fibrosis score was increased above the cut-off
value among the patients with a “non-worsened” status re-
garding the %FVC at six months, those with an increased
HRCT fibrosis score above the cut-off value demonstrated
a significantly poorer prognosis (HR 2.192, 95% CI 1.003-






al. The overall survival of the “worsened” status group at six months

















normal attenuation reticular abnormality traction bronchiectasis honeycombing
Figure 3 The changes in the extent of each HRCT finding after the initial diagnosis. The ratios of the radiological findings of reticular
abnormalities, traction bronchiectasis and honeycombing increased over time, while the ratio of normal attenuations decreased.
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In the present study, we first clarified that changes over
time in HRCT findings in combination with the %FVC
predict the prognosis of patients with IPF. In addition,
our data demonstrated that the new HRCT scoring sys-
tem is helpful for identifying patients with an adverse
prognosis when used in combination with pulmonary
function examinations. These results indicate that the
new HRCT scoring system is an appropriate and subject-
ive method for monitoring IPF patients.
In the present study, the %FVC was found to be a base-
line factor predicting the prognosis of patients with IPF. In
addition, the patients with a decline of ≥ 10% in the abso-













Figure 4 The changes in the total HRCT fibrosis score after the
initial diagnosis. The HRCT fibrosis score significantly increased at
six and 12 months compared to the initial diagnosis (*p < 0.001).(the “worsened” status group) had a poor prognosis in this
study. Furthermore, these patients demonstrated a ten-
dency toward further declines in the %FVC over the sub-
sequent six months and to have a worse prognosis. On the
other hand, the vast majority of the patients in the present
study (93.9%) exhibited an “improved” or “stable” status
six months after the initial diagnosis and tended to not
show any changes in the %FVC over the following six
months. Changes in the %FVC are an indicator of disease
progression as a surrogate endpoint for overall survival
[15-17]; therefore, pulmonary function examinations are
commonly used to monitor patients with IPF. However,
the clinical course of IPF varies widely [18,19], and some
patients may exhibit a sudden decrease in their pulmonary
function [20]. The variety in the clinical course of patients
with IPF makes it difficult to identify those with a poor
prognosis based on the results of pulmonary function tests
alone, and it is therefore necessary to establish a proper
monitoring method enabling clinicians to identify the pa-
tients most likely to have a poor prognosis from a different
perspective.
Previous reports regarding the relationship between
HRCT findings and survival rates in IPF patients have been
published [21-23]. The CT visual score [24] and fibrotic
score [2,25] determined using various software tools [26]
to evaluate findings of reticular abnormalities and honey-
combing are useful for assessing the prognosis of IPF. Fur-
thermore, some reports [27,28] have evaluated changes in
HRCT findings in patients with IPF over time using a scor-
ing system. In the present study, we used the new HRCT
scoring system-based grading scale. The new HRCT scor-
ing system was designed to reflect all findings of the UIP
pattern described in the 2011 IPF guidelines. The grading
scale reflects the progression of pulmonary fibrosis. Add-
itionally, we graded the HRCT findings in order of priority
from honeycombing to traction bronchiectasis, reticular
abnormalities and normal attenuation. Furthermore, we set
the monitoring period at six-month intervals in order to
accurately investigate the appropriate duration for moni-
toring disease progression in patients with IPF.
A B C
Figure 5 High-resolution CT findings of the patient with an adverse prognosis. The patient was a 78-year-old man with IPF. HRCT scan at
the level of lower left lobe shows fibrosing changes from the baseline (A) at six (B) and 12 months (C). HRCT images at diagnosis of IPF show
subpleural predominant interstitial fibrosis, traction bronchiectasis (arrowheads) and honeycombing (arrows). The overall HRCT fibrosis score at
the baseline, six and 12 months were 151.3, 162.5 and 185.8, respectively. This patient died 20 months after initial diagnosis.
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not found to be a factor predicting the prognosis in this
study, although the extent of changes in the HRCT fi-
brosis score within at least the first six months after the
initial diagnosis did reflect the prognosis, and acceler-
ation in the findings of pulmonary fibrosis on radiology
had an impact on the final outcome. In terms of the ex-
tent of acceleration of fibrosis, the number of fibroblas-
tic foci has previously been shown to have an impact on
the prognosis in pathological studies [5,29,30] and is an
important factor associated with the clinical state of IPF.
Additionally, the combined evaluation of radiological as-
sessment within the first six months after the initial
diagnosis with a change in %FVC facilitated the extrac-
tion of patients with a poor prognosis, who were other-
wise hidden within the group with stable %FVC values.








Days from initial diagnosis
Patients with elevated cut-off value (n=34)
Patients without elevated cut-off value (n=64)
Patients with elevated cut-off value censored
Patients without elevated cut-off value censored
(A)
Log-rank test p=0.0142
(HR: 2.435 ; 95% CI: 1.196 to 4.962)
Figure 6 The difference in the overall survival whether the cut-off val
value was significantly worse than that of patients with value below the cu
(B) months were 6.7 and 13.5, respectively.using only HRCT, the %FVC was found to be a baseline
factor indicating the prognosis, and pulmonary function
examinations (as a monitoring method) in combination
with the assessment of HRCT findings were useful for
inferring the detailed prognosis.
From the standpoint of early detection of concomitant
lung cancer [31,32], it is important to avoid overlooking
small lung cancer lesions, even on routine HRCT (instead
of incremental CT). Furthermore, in line with the 2011 re-
visions to the guidelines, it is anticipated that diagnosing
IPF using only HRCT will become more common in the
future, as this modality also facilitates the determination
of responsiveness to treatment [33], and it is believed that
HRCT examinations will continue to play a pivotal role in
the diagnosis and management of IPF.
There are several limitations associated with this











(HR: 2.637 ; 95% CI: 1.363 to 5.100)
Patients with elevated cut-off value (n=44)
Patients without elevated cut-off value (=54)
Patients with elevated cut-off value censored
Patients without elevated cut-off value censored
ue elevated or not. The overall survival of patients with an elevated









Days from initial diagnosis
Stable without elevated cut off value (n=62)
Stable with elevated cut off value (n=30)
Worsened without elevated cut - off value (n=3)
Worsened with elevated cut-off value (n=3)
Stable without elevated cut off value censored
Stable with elevated cut off value censored
Worsened without elevated cut - off value censored
Worsened with elevated cut - off value censored
Figure 7 The results of a comparison of the overall survival
between the IPF patient groups. Among the patients in whom
the %FVC was of “non-worsened” status at six months, the patients
with an increased HRCT fibrosis score above the cut-off value
demonstrated a significantly poorer prognosis, with a decreased
overall survival, than those without such an increase (HR 2.192, 95%
CI 1.003-4.791; p = 0.0491).
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may have influenced the assessments of the prognosis.
Second, only 19.1% of the patients were allocated to the
group in which a decrease of ≥ 10% in the absolute value
of FVC was observed 12 months after the initial diagnosis
(the “worsened” status group). This group is considerably
smaller than that observed in previous studies, including
a proportion of 36.9% in a Japanese study of pirfenidone
[34] and 41.9% in a study of etanercept [35]. The fact that
all patients who died within one year of the initial diag-
nosis were eliminated in the present study may be a fur-
ther limitation. Third, the diagnosis of IPF was restricted
to patients in whom the UIP pattern was diagnosed using
HRCT and did not include those with a possible UIP pat-
tern. In other words, IPF patients requiring pathological
consideration were not included, and the study therefore
does not reflect the entity of IPF as a whole. Fourth, this
work was carried out jointly across multiple facilities, re-
stricted to Japanese IPF patients. For this reason, when
interpreting the results, it is necessary to consider poten-
tial racial selection bias, etc. Finally, this study was pri-
marily based on HRCT findings obtained using a visual
score, with good interobserver variation for the assess-
ment of the presence/absence of each HRCT finding.
However, among the various radiological factors, honey-
combing has previously been reported [36] to have an in-
sufficient rate of concordance, and radiological changes
in this feature over a one-year period are small; thus,
it is necessary to pay attention to inaccuracies in themanual scoring system used for the radiological CT
examinations.
Conclusions
The HRCT scoring system-based grading scale is useful
for inferring the prognosis in patients with IPF and, in par-
ticular, facilitates the extraction of patients with a poor
prognosis who cannot be identified using only pulmonary
function examinations. These findings have the potential
to improve the day-to-day treatment of IPF patients, in-
cluding the ability to determine the correct time at which
to initiate treatment, including the administration of new
agents such as pirfenidone [37] and BIBF1120 [38] as well
as lung transplantation.
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